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A prospective analysis of renal artery stent revascularization
with distal embolic protection in a high-risk patient
population with ischemic nephropathy is presented. A total
of 63 patients (median age 70.2 years, range 54–86 years) had
significant atherosclerotic stenosis of 83 renal arteries
documented on pre-procedural imaging. All patients had
baseline chronic renal insufficiency with a documented
deterioration in renal function in the 6 months before
revascularization. The endovascular technique used in all
patients involved primary passage of an embolic filter into
the distal main renal artery followed by primary stent
deployment with a balloon expandable stainless steel stent.
The filter baskets were recaptured and contents submitted
for pathological analysis. At 6 months post-intervention, 97%
of patients demonstrated stabilization or improvement in
renal function. Only 3% of patients had an inexorable decline
in renal function, unchanged by the intervention. After a
mean follow up of 16.0 months (6–27), 94% of patients
demonstrated stabilization or improvement in renal function.
One patient suffered an acute post-procedural deterioration
in renal function. In total, 60% of the filter baskets contained
embolic material. This study confirms the technical feasibility
of renal artery stent deployment with adjuvant embolic
protection. The excellent results for renal preservation at 6
months post-intervention also suggest that a distal embolic
protection device may improve the impact of percutaneous
renal revascularization on progressive deterioration in renal
function. The postulated mechanism is through the
prevention of atheromatous embolization and the embolic
yield from the distal filters supports this hypothesis. Patients
most likely to receive the greatest benefit are those with mild
baseline chronic renal insufficiency and a recent decline in
renal function.
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Atherosclerotic renal artery stenosis is common, especially in
older patients with atherosclerotic disease in other arterial
systems.1 Atherosclerotic renal artery stenosis is a significant
cause of refractory hypertension and chronic renal insuffi-
ciency (CRI),2 especially in the elderly.3 It is known that
hemodynamically significant renal artery stenoses progress.3,4
Renal artery occlusion is associated with a loss of renal mass
and deterioration in renal function.5 Unfortunately, the
results of renal artery angioplasty and stenting for ischemic
nephropathy have been mixed.6–8 Of concern is the reported
incidence (10–20%) of procedure-related deterioration in
renal function following renal artery stent revasculariza-
tion.9–11 Many have postulated that atheromatous emboliza-
tion is a major cause of this acute decline in renal function
and likely contributes to the mixed long-term results with
this procedure. We report the results of primary renal
angioplasty and stenting with distal embolic protection in a
high-risk patient population with ischemic nephropathy.
RESULTS
The patient group included 40 male (63%) and 23 female
(37%) subjects with a median age of 70.2 years (54–86).
Before treatment, 48 patients (76%) had a moderate decrease
in estimated glomerular filtration rate (eGFR) (Kidney
Disease Outcome Quality Initiative (K-DOQI) stage 3, eGFR
30–59 ml/min) and 15 patients (24%) had a severe decrease in
eGFR (K-DOQI stage 4, eGFR 15–29 ml/min). For the
purposes of more detailed analysis, the K-DOQI stage 3
patients were subdivided into two groups: K-DOQI stage 3A
(eGFR 41–59 ml/min) and K-DOQI stage 3B (eGFR
30–40 ml/min). A total of 23 patients were classified as
K-DOQI stage 3A (termed ‘mild CRI’ in this study) and
25 patients were classified as K-DOQI stage 3B (termed
‘moderate CRI’ in this study). A total of 44 patients (70%)
were also hypertensive, receiving an average of 2.3 anti-
hypertensive medications. The normotensive patients had a
mean systolic blood pressure of 126 mm Hg (105–137) and
a mean diastolic blood pressure of 84 mm Hg (72–88).
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The hypertensive patients had a mean systolic blood pressure
of 164 mm Hg (140–196) and a mean diastolic blood pressure
of 108 mm Hg (90–125).
The alterations in renal function following stent revascu-
larization with distal embolic protection at 6 months post-
intervention are summarized in Table 1. There were
improvements in sCRN for patients with K-DOQI stage
3A, 3B, and 4 pre-intervention CRI. The response rates are
summarized in Table 2. Overall, 97% of patients had
improvement or stabilization of renal function at 6 months
post-intervention. Two patients (3%) had progressive
deterioration in renal function after intervention. A Pearson
w2 test was performed on the data in Table 2 to assess if the
impact on CRI after renal artery stent revascularization was
significantly better for patients with mild CRI pre-interven-
tion (K-DOQI 3A) as compared to patients with more severe
CRI pre-intervention (K-DOQI 3B,4). In all, 52% of the mild
group improved compared to 33% of the moderate/severe
group, but this effect did not reach statistical significance
(w2¼ 2.4, P¼ 0.12). The mean follow-up period was 16.0
months (6–27). Few patients suffered a progressive decline in
renal function after 6 months post-intervention (Figure 1)
with 94% of patients having improvement or stabilization of
renal function at latest follow-up.
One patient with baseline mild CRI suffered an acute
deterioration in renal function after the procedure. In this
patient, the pre-intervention sCRN was 140 mmol/l and
increased to 170 mmol/l at 24 h post-procedure. During the
procedure marked intra-renal arterial vasospasm was en-
countered, only partially responsive to repeated boluses of
glyceryl trinitrate. This deterioration was asymptomatic. The
distal filter did contain embolic debris. The most recent
sCRN had improved to 160 mmol/l, 12 months after the
initial intervention.
The distal embolic protection baskets contained macro-
scopic embolic contents in 38 of 63 cases (60%). The filter
contents included fresh thrombus, chronic thrombus,
atheromatous fragments, and cholesterol clefts. The remain-
der of the baskets was either empty or contained insufficient
material to sustain processing. In all, 80% (20/25) of the
patients with improved renal function after renal artery stent
revascularization had filters with atheromatous embolization
contents compared with 45% of the patients (17/38) with
stabilized, unchanged decline or acute deterioration in renal
function (Table 3). A Pearson w2 test was performed on the
data in Table 3 to assess if the impact on CRI after renal
artery stent revascularization was significantly better for
patients with or without filter contents. Patients with positive
filter contents had a significantly improved outcome after
revascularization compared to those without filter content
(w2¼ 6.7, P¼ 0.01).
All patients underwent a 6 weeks and 6 months post-
procedural renovascular Doppler study. All treated renal
arteries (100%) were patent at 6 weeks with no evidence of a
significant residual stenosis. Five patients (8%) had sig-
nificant instent restenosis demonstrated on renovascular
Doppler at 6 months post-intervention. These patients
underwent confirmatory angiography and were managed
with repeat balloon dilatation, with embolic protection. No
patients had cure of hypertension after the procedure,
however 55% (24/44) of patients required fewer antihyper-
tensive agents (mean number of medications 1.8/patient).
Table 1 | Serum creatinine after renal artery stent revascularization with protection according to level of pre-intervention renal
insufficiency
Level of pre-intervention CRI
(K-DOQI stage) N
Mean (s.d.a) pre-intervention
serum creatinine
(lmol/l)
Mean (s.d.a) 6-months
post-intervention serum
creatinine (lmol/l)
Change (s.d.a) from
pre-intervention to 6 months
post-intervention serum
creatinine (lmol/l)
Mild (3A) 23 133 (17) 121 (22) 11.3 (15.5)
Moderate (3B) 25 160 (22) 154 (22) 6.8 (16.5)
Severe (4) 15 223 (48) 213 (46) 10.0 (17.3)
CRI, chronic renal insufficiency; K-DOQI, Kidney Disease Outcome Quality Initiative.
as.d.=standard deviation.
Table 2 | Impact of renal artery stent revascularization with protection on renal function at 6 months post-intervention
stratified to level pre-intervention chronic renal insufficiency
Level of pre-intervention renal impairment
K-DOQI 3A (mild) K-DOQI 3B (moderate) K-DOQI 4 (severe) Total
N (%) N (%) N (%) N (%)
Improved 12 (52%) 8 (32%) 5 (33%) 25 (40%)
Stabilized 11 (48%) 15 (60%) 10 (67%) 36 (57%)
Unchanged decline 0 (0%) 2 (8%) 0 (0%) 2 (3%)
Total 23 25 15 63
CRI, chronic renal insufficiency; K-DOQI, Kidney Disease Outcome Quality Initiative.
Improvement in renal function was most marked in the mild CRI (K-DOQI 3A), but this effect did not reach statistical significance (w2=2.4, P=0.12).
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In the hypertensive group, there was a reduction in both
mean systolic blood pressure (132 mm Hg, range 118–162)
and mean diastolic blood pressure (92 mm Hg, range 80–108).
The impact of renal artery revascularization on the pre-
procedural slope of decline in renal function has been
demonstrated (Figure 2). By extrapolating the mean pre-
procedural slope of decline, it is estimated that both these
patient groups would require renal replacement therapy
between 15 and 18 months. Conservatively, assuming only
15% of these elderly patients with end stage ischemic
nephropathy will undergo dialysis,12 it is estimated that nine
of the 63 patients would require dialysis by 18 months
without intervention. In 2005, the mean patient annual
dialysis cost is NZD $55 000, so the savings in dialysis costs by
intervening in these 63 patients is estimated at NZD $495 000
(9 $55 000). By comparison, the interventional costs for
treating these 63 patients was NZD $299 250, based on an
individual patient cost of NZD $4750 (including procedural
costs and in-patient hospital stay).
DISCUSSION
The relationship between atherosclerotic renal artery stenosis,
chronic renal insufficiency, resistant or refractory hyperten-
sion, and ischemic nephropathy is complex. The prevalence of
renal artery stenosis is high in patients with symptomatic
atherosclerotic disease in other arterial systems, particularly
coronary, cerebral, and peripheral arteries.1,13,14 In these
patients, renal artery stenosis provides a marker of higher
mortality.13 The natural history of hemodynamically signifi-
cant renal artery stenosis is the subject of some debate.
Hemodynamically significant renal artery stenoses frequently
progress with risk factors for progression including severe
stenoses, high systolic blood pressure, or diabetes mellitus.3,4
Progression to occlusion is uncommon15 but occlusion is
associated with loss of renal mass and decreased renal
function.5 Ischemic nephropathy is defined as diminished
renal excretory function as a result of impaired renal
perfusion.16 In older patients with main renal artery stenosis,
other factors also contribute to chronic renal impairment.
Nephrosclerosis refers to primary disease in parenchymal renal
arteries resulting in glomerular atrophy, tubulointerstitial
lesions, and fibrosis.17 These changes are seen in elderly and
hypertensive patients and are irreversible. Meticulous control
of blood pressure is required to prevent further deteriora-
tion.17 In addition, recurrent ‘silent’ cholesterol embolization
of cholesterol debris from aortic atheroma may contribute to a
gradual, inexorable deterioration in renal function, and may
be indistinguishable from nephrosclerosis.17
Despite these complex relationships, there is evidence that
revascularization of main renal artery stenoses can improve
renal function. Open surgical revascularization has been
reported to stabilize or improve renal function in the
majority of patients18 but is associated with a significant
peri-operative morbidity and mortality in this older patient
group. The results of endovascular revascularization per-
formed for preservation of renal function have been mixed,
with a paucity of controlled trial data. Meta-analyses,6,8
including available randomized controlled trial data,19 have
failed to show benefit of renal artery angioplasty in
improving or preserving renal function (although the studies
were not designed to address this issue). More recent single
center series have found that the majority of patients
experience stabilization of renal function7 with a favorable
change in the slope of renal function regression lines20 but a
relatively low incidence (15–30%) of improvement in renal
function.7 Stenting of atherosclerotic stenoses of the renal
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Figure 1 | Long-term response of reciprocal sCRN to renal
angioplasty with protection for mild, moderate, and severe
pretreatment CRI groups.
Table 3 | Impact of renal artery stent revascularization with
protection on renal function at 6 months post-intervention
stratified by presence of material in embolic protection
baskets
Filter Improved
Stabilized or
unchanged decline Total
contents n (%) n (%) n (%)
Positive 20 (80) 18 (47) 38 (60)
Negative 5 (20) 20 (53) 25 (40)
Total 25 (100) 38 (100) 63 (100)
Patients with positive filter contents had a significantly improved outcome after
revascularization compared to those without filter contents (w2=6.7, P=0.01).
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Figure 2 | Response in reciprocal sCRN to renal angioplasty with
protection – actual response after intervention (bold line) and
projected reciprocal sCRN without intervention (dotted line).
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artery ostium is associated with improved procedural success,
patency, and reduced restenosis rates,21,22 when compared to
angioplasty alone although a significant benefit in blood
pressure or renal function response has not been proven.21
There are few non-invasive predictors of a favorable
response to revascularization in ischemic nephropathy.
Patients with certain baseline characteristics (mild renal
impairment, severe renal artery stenosis, non-diabetics, and
those requiring ‘global renal artery revascularization’) are
more likely to experience a favorable impact on renal
function.7,23,24 The most important predictor appears to be
the rate of decline (slope of regression lines based on the
reciprocal of the serum creatinine measurement) in renal
function before the intervention. Patients with a rapid
deterioration in renal function experience greater benefit in
renal function with stent revascularization than those with
stable chronic renal impairment.25,26
Many studies of endovascular revascularization in is-
chemic nephropathy report a procedure-related acute decline
in renal function of 10–20%.9,21,27 While other causes such as
contrast-related nephropathy and arterial dissection may
contribute, a major contributor to procedure-related decline
in renal function is likely to be embolization of atheromatous
debris (cholesterol atheromatous embolization). Atheroma-
tous emboli may produce acute arterial occlusions but
secondary inflammatory changes (localized arteritis with
intimal thickening and cellular proliferation) may be more
damaging.25 There are two forms of atheromatous emboliza-
tion – systemic and local. Systemic atheromatous emboliza-
tion may occur spontaneously (usually as a result of a
penetrating atheromatous aortic ulcer), but is more fre-
quently reported after catheter or surgical manipulation of a
severely atheromatous aorta.28,29 The incidence of systemic
atheromatous embolization is uncertain. Although patients
may present with a sudden onset of renal failure, a more
frequent presentation is a silent clinical course (owing to
functional renal reserve) with a progressive decline in renal
function over weeks to months.25,29 Patients often present
with other systemic (e.g. eosinophilia) or embolic (digital,
mesenteric lesions) symptoms. The prognosis is poor, and
there are no specific treatment options.30 Local atheromatous
embolization refers to embolization of a specific organ
following endovascular or surgical manipulation of the artery
perfusing that organ. Endovascular intervention at arterial
sites such as the carotid bifurcation31 and saphenous vein
graft32 is known to produce distal atheromatous emboliza-
tion. During carotid endovascular procedures, guidewire and
catheter manipulation and especially angioplasty can produce
distal atheroembolization.33 Ex vivo manipulation of the
atheromatous renal artery ostium has been shown to release
large numbers of embolic particles with angioplasty, and
stenting the most embologenic part of the procedure.34 The
incidence of embolization produced by primary passage of a
distal filter through a critical renal artery stenosis is unknown
but this is likely to be less problematic with the development
of lower profile filter systems.
There are few case reports35,36 and feasibility reports37
describing the technical success of renal embolic protection
devices during stent revascularization. Both distal occlusion
balloons37 and distal filters37–39 have been used. Renal artery
anatomical variants such as early main renal artery branching
may limit the use of a distal embolic protection device (filter
or occlusion balloon) in a minority of patients. A theoretical
advantage of distal filters is that they maintain renal
parenchymal perfusion throughout the revascularization
procedure. In vitro renal parenchymal tolerance to ischemia
(‘warm ischemia’) is not well defined with most literature
describing warm ischemic times during renal transplanta-
tion,40 renal trauma,41 or supra-aortic cross-clamping during
aortic surgery.42 In many of these situations, the renal
parenchyma is normal and the effect of warm ischemia on a
kidney already damaged by chronic ischemia is not known.
Distal occlusion balloons have the potential advantage that
they facilitate capture of embolic particles of all sizes. Ex vivo
studies have demonstrated that although large numbers of
100–500 mm diameter particles are released during endovas-
cular manipulation of the atheromatous renal artery ostium,
there are also large numbers of smaller particles (e.g.
20–40 mm) released.34 The deleterious effect of these smaller
particles in the renal circulation is not known, but they are
about the size of the human efferent arteriole34 and have been
suspected to cause significant ischemia in the cerebral
circulation.43
We have previously reported our early experience with
protected renal artery stent revascularization.38 That report
included a ‘learning curve’ and the technique was modified
during the series. This current report describes a separate
patent cohort and outlines our recent experience of renal
artery stent revascularization with distal protection in a more
uniform high-risk patient population with ischemic nephro-
pathy. The same technique (primary filter passage, primary
stenting) was used in all patients. Aggressive pre-procedural
hydration was uniform and no patients received N-acetyl-
cysteine. We used low volumes of iodinated contrast in all
procedures as we had previously found the reduced radio-
opacity of Gadolinium chelates in abdominal arteries to
negatively impact on technical success and procedure time.
Excellent pre-procedural demonstration of renal artery
anatomy with contrast-enhanced magnetic resonanceangio-
graphy, selection of appropriate shaped guide catheters, and
the reduced profile of distal filters facilitated both the
‘primary passage’ technique and low contrast volumes. The
impact of these factors on improved outcomes has been
described by others.39,44,45 The majority of our patients
(97%) demonstrated an improvement or stabilization in
renal function at 6 months post-intervention. The response
was sustained over a mean follow up of 16 months
(maximum 27 months) after protected renal artery
intervention.
The results of our current series are better than most
reported in the literature, probably owing to the use of
embolic protection. The yield of embolic debris from the
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distal baskets during pathologic analysis supports this
conclusion. A significant percentage (60%) had macroscopic
debris in the distal protection basket. The high embolic yield
is not surprising given the potential atheromatous burden of
the abdominal aorta (Figure 3). The embolic yield has varied
in the literature37,38 and appears to be influenced by the type
of embolic protection used and the method of pathological
analysis. In this series, only macroscopically visible debris was
analyzed. Film-like debris was frequently seen within the
retrieved filter but this was not analyzed. In other series, an
aspirated effluent has been collected when a distal occlusion
balloon has been used.34,37 Microscopic analysis of this
effluent has facilitated more accurate assessment of particle
numbers and size.
Optimizing results with renal artery stent revasculariza-
tion requires a number of adjuvant techniques to minimize
procedure-related renal injuries. Adequate peri-procedural
intravenous hydration appears most important, including
pre- and post-intervention.46 All patients in this series had
overnight intravenous hydration using normal saline before
the intervention and this was continued for at least 12 h post-
procedure. Initial evidence that the antioxidant N-acetylcys-
teine may also be nephro-protective47 has not been
confirmed by more recent reports.48 N-acetylcysteine was
not used in this series. Intra-arterial Gadolinium chelates
may be used instead of iodinated contrast media during the
endovascular procedure49 and appear to be less nephrotoxic50
in the doses used.44 Gadolinium offers lower radio-opacity50
and we have previously found this problematic for abdo-
minal interventions. Carbon dioxide can also be used.51
It is likely that primary arterial stenting in patients with
CRI is cost effective.9 However, there is no data evaluating the
cost effectiveness of embolic protection in renal artery
revascularization. Many patients with severe CRI secondary
to ischemic nephropathy are elderly and only 10–15% will
require renal replacement therapy52 usually in the form of
dialysis. Many of the non-dialyzed patients will die due to
their underlying vascular disease.53 Although we have made a
number of assumptions, our analysis suggests that stent
revascularization with embolic protection is very cost
effective, predominantly due to the exorbitant costs of renal
replacement therapy (dialysis, transplantation).
Further advances in equipment for renal stent revascular-
ization include the development of anti-restenosis therapies,
improvements in embolic protection systems, and magnetic
resonance compatible stents.54 The overall incidence of
instent restenosis in the renal artery is estimated at between
15 and 20%,7,21 but appears to be lower for stents dilated to
diameters of 6–7 mm.55 In this study, renal artery stents were
aggressively dilated to 6–7 mm diameter possibly contributing
to a low 6-month restenosis rate of 8%. Anti-restenosis
therapies include the use of drug eluting stents, thinner stent
struts facilitated by materials such as chromium cobalt,56 and
antiplatelet therapies such as aspirin and clopidigrel.57 Renal
artery anatomy provides unique challenges for embolic
protection, and systems customized for the renal artery are
yet to be developed. Improvements include reducing the
profile of distal filters to facilitate primary filter passage and
shortening the combined filter-stent length to cope with
anatomical variants such as early main renal artery branch-
ing. Embolic protection will not prevent all adverse outcomes
related to poor case selection (including treatment of non-
atherosclerotic renal artery disease), technical errors in stent
positioning, and in-stent restenosis. However, we believe that
procedure-related atheromatous embolization is a major
contributing factor to poor outcomes.
There are limitations to this study, most importantly the
lack of prospective comparisons to an identical patient
cohort undergoing renal artery stent revascularization with-
out embolic protection. The results of this single center
prospective evaluation supports performance of such a study.
There are randomized, controlled trials comparing best
medical therapy to best medical therapy plus stent revascu-
larization currently enrolling,58 one of which includes the use
of distal filters.59 The impact on renal function is not as
accurate as a measured glomerular filtration rate; however, as
consistent estimations were made on each patient at each
point of follow up, the results and trends are reasonably
accurate. Although the duplex ultrasound studies were not
interpreted by an independent expert, all images were
evaluated by two different investigators, with discrepancies
adjudicated by a third investigator.
This report demonstrates the technical feasibility of
protected renal artery stenting using a technique of primary
filter passage and primary stenting. The excellent renal
preservation results achieved in this series of high-risk
patients suggests that embolic protection can make a positive
contribution to patient outcome in selected patients under-
going renal artery stent revascularization.
a bLeft Left
Left
c Post-stenting
7 mm × 15 mm stent
7 mm balloon
Figure 3 | Stent revascularization with distal protection of a
solitary functional kidney. (a) Primary passage of a distal filter
(arrow) through a critical stenosis via a guide catheter, deployed in
the distal main renal artery (arrow). (b) Accurate positioning of a
balloon expandable stent (Palmaz Genesis stent, Cordis Endovascular)
at the renal artery ostium. Note the atheromatous abdominal aorta
(arrow) as a potential embolic source. (c) Primary stenting of the left
renal ostial stenosis with a balloon expandable stent (Palmaz Genesis
stent, Cordis Endovascular) and the distal filter in place.
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MATERIALS AND METHODS
Prospective analysis was performed on 63 consecutive patients (83
renal arteries) who presented with atherosclerotic renal artery
stenosis and baseline chronic renal insufficiency (defined by an
estimated glomerular filtration rate of less than 50/ml/min/1.73 m2)
as a result of renal ischemia. These patients were treated at a single
institution (Auckland City Hospital) between May 2002 and
February 2005 with balloon angioplasty and stent deployment with
an embolic protection device. All patients provided informed
consent for the procedures and Hospital Ethical Committee
approval was obtained.
The pre-intervention diagnosis of renal artery stenosis was made
with contrast-enhanced magnetic resonance angiography in all
patients (Figure 4a). All stenoses involved the main renal artery
ostium. Pretreatment renal artery anatomy is summarized in Table 4.
The vast majority of patients (58 patients) underwent ‘global
revascularization’, defined in this study as revascularization of
bilateral renal artery stenosis or renal artery stenosis supplying a
solitary functional kidney. In 20 patients, bilateral high-grade renal
artery stenosis was treated during a single procedure. In 38 patients,
the contralateral kidney was absent or was not contributing
significantly to total renal function (renal artery occlusion, diffusely
small caliber renal artery, atrophic kidney). In five patients, the
contralateral main renal artery was of normal caliber, but abnormal
renal function and hypertension were present. During the study
period, an additional four patients could not be treated with distal
embolic protection for arterial anatomical reasons (defined on
magnetic resonance angiography) and were excluded from the study.
In three patients, there was early branching of the main renal artery
(defined as within 20 mm of the ostium) into equal-sized branches.
In one case, a solitary functioning kidney was supplied by two
equal-sized arteries. All patients had objective deterioration in renal
function (using serial serum creatinine measurements) during the 6
months before the intervention. No patient had clinical, biochem-
ical, or urinalysis evidence of other potentially treatable causes of
chronic renal insufficiency besides ischemic nephropathy.
Patients were admitted to hospital for overnight intravenous
hydration (normal saline) before the intervention, which was
continued for approximately 24 h after the procedure. Iodinated
contrast (Ultravist 300, Schering, Berlin, Germany – 300 mgI/ml) was
used in all patients, with a mean contrast volume of 37 ml (28–57). A
retrograde femoral artery approach was used for vascular access in 61
patients. In two patients, brachial artery access was used. All patients
received intra-arterial heparin (5000 IU) and glyceryl trinitrate
(mean 144mg/patient) during the procedure. The Angioguard XP
emboli capture guidewire system (Cordis Endovascular, A Johnson &
Johnson Company, Miami Lakes, FL, USA) was used in 73 arteries.
This device consists of a 0.014 inch guidewire with a polyurethane
filter and Nitinol framed ‘basket’ at the distal end. The filter has
100mm pores and is supported by eight Nitinol struts. In 10 arteries,
the Filterwire EZ emboli protection system (Boston Scientific,
Natick, MA, USA) was used. This device also consists of a 0.014 inch
guidewire with a polyurethane filter at the distal end but with 110mm
pores and a Nitinol loop rather than struts.
Flush abdominal aortography using a small volume of contrast
was initially performed to assist in accurate localization of the renal
artery ostium. An appropriately shaped guiding catheter was then
introduced and positioned. A ‘primary filter passage’ technique was
used in all cases. This involved primary passage of the distal
protection device through the stenosis with deployment of the
device in the distal main renal artery (Figure 4b). In seven patients
(eight arteries), a small arterial branch arising within 20 mm of the
main renal artery ostium could not be protected. In these cases, the
filter was deployed into the distal main renal artery beyond the
branch. Primary stenting of the stenosis was then performed over
the distal protection device guidewire with optimum positioning of
the stent using small contrast boluses (Figure 4c). No patients
required pre-dilatation to assist with placement of the stent. The
‘primary filter passage’ technique was successful in all 63 patients
although four renal arteries required the use of a ‘buddy wire’ to
facilitate filter passage (Figure 4d and e). In all cases, a short (length
12–15 mm) balloon expandable stent was deployed. When the
Angioguard system was used (73 arteries), a Palmaz Genesis stent
(Cordis Endovascular, A Johnson & Johnson Company, Miami
a
b
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e
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Dr Holden
Right
Right
Post-stent insertion
6 mm × 12 mm
Figure 4 | Bilateral atherosclerotic renal artery stenoses treated
with stent revascularization with distal protection. (a) Contrast-
enhanced magnetic resonanceangiography confirms bilateral ostial
renal artery stenoses (arrows), more severe on the left. (b) Primary
passage of a distal filter (Angioguard XP, Cordis Endovascular, arrow)
via a guide catheter is possible on the right. (c) Primary stenting of
the right renal ostial stenosis with a balloon expandable stent
(Palmaz Genesis stent, Cordis Endovascular, arrow). (d) The more
severe left renal ostial stenosis required initial passage of a 0.014 inch
‘buddy wire’ (long arrow) before coaxial passage of a filter (short
arrow). (e) Post-stenting angiography. Note the poor flow through
the filter (arrow) due to embolic debris. (f) Recaptured distal
protection filter with macroscopic atheromatous embolization
material.
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Lakes, FL, USA) was deployed (Figure 4). When the Filterwire
system was used (10 arteries), an Express SD stent (Boston Scientific
Corporation, Natick, MA, USA) was deployed (Figure 5). The
majority of stents (53%) were inflated to a diameter of 6 mm with
the remainder inflated to 7 mm (47%). No residual lumen diameter
was less than 6 mm. After completion angiography, the distal basket
was recaptured and sent for pathologic analysis in formalin.
Macroscopically visible filter contents were removed and studied
by microscopy (Figure 4f).
All patients had serum creatinine (sCRN) measurements before
and within 24 h following the procedure. Pre-intervention renal
function was measured using an estimated glomerular filtration rate
(eGFR) calculated using the abbreviated Modification of Diet in
Renal Disease equation.60 The severity of pre-intervention CRI was
classified using the Kidney Disease Outcome Quality Initiative
(K-DOQI).60 All patients underwent regular clinical and bio-
chemical assessment at hospital outpatient clinics during the post-
procedural surveillance period. Data collected included sCRN and
electrolytes (at 3 monthly intervals), patient weight, blood pressure,
and relevant clinical symptomatology. The primary study measures
were sCRN at day 1 and 6 months post-procedure. The day 1 sCRN
was used to detect any acute procedure-related deterioration in renal
function. The 6 months sCRN was used to measure renal function at
a sufficient interval post-intervention to assess any harmful effects of
atheromatous embolization. A baseline renovascular Doppler study
was performed at 6 weeks after the procedure and repeated at
6 months in all patients. The renovascular Doppler studies included
color and power Doppler interrogation of the stented arterial lumen,
measurement of angle-corrected peak systolic velocities within and
beyond the stent, calculation of renal–aortic flow velocity ratio, and
measurement of acceleration time within intra-renal segmental
arteries. The diagnosis of stent patency and instent restenosis was
made using validated Doppler criteria.12,61
Alterations in renal function following the procedure were
classified as improved, stabilized, progressive deterioration or acute
deterioration. An acute deterioration was defined as a 20%
reduction in sCRN occurring within the first 24 h post-procedure.
Improved renal function occurred when the 6 months post-
procedure calculated sCRN was 20% greater than the renal function
measured before the procedure. Conversely, a progressive deteriora-
tion in renal function occurred when the 6 months sCRN was 20%
worse than baseline. Alterations in renal function were also assessed
using the most recent sCRN and classified in the same way.
A formal cost–benefit study of renal artery stent revascularization
with adjuvant embolic protection in this ischemic nephropathy
patient group was not undertaken, but some analysis was
performed. The pre-procedural slope of decline in renal function
(utilizing the reciprocal of the serum creatinine) seen in all patients
was extrapolated to calculate the average theoretical delay until renal
function had declined to a level requiring renal replacement,
assuming intervention had not been performed (Figure 2). Using
local cost estimates for renal dialysis and transplantation, cost–
benefit calculations were made.
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